UBS Starts McKesson (MCK) at Neutral
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
UBS initiates coverage on McKesson (NYSE: MCK) with a Neutral rating and a price target of $182.00.
Analyst Michael Cherny commented, "We are initiating coverage on McKesson with a Neutral rating and a $182 price target. McKesson has been one of the steadiest performers across healthcare for the last decade, with strong growth in core distribution (pharma and medical) and consistent expansion through M&A. MCK is also generating strategic value for the Technology Solutions business, a long-term underperformer. While headwinds such as branded drug pricing and client losses will slow growth in the short-term, the overhang and uncertainty surrounding drug pricing ahead of the election leaves limited upside for multiple expansion back to normalized levels, thereby capping upside potential."
Shares of McKesson closed at $165.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Community Health (CYH) to Underperform
- Needham & Company Raises Price Target on AXT, Inc. (AXTI) Following 3Q Beat and Guidance
- H.C. Wainwright Starts Ohr Pharmaceutical (OHRP) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!